Capital Investment Advisors LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 6.3% during the first quarter, according to its most recent filing with the SEC. The fund owned 112,077 shares of the company’s stock after buying an additional 6,643 shares during the period. Johnson & Johnson comprises 1.1% of Capital Investment Advisors LLC’s portfolio, making the stock its 19th largest position. Capital Investment Advisors LLC’s holdings in Johnson & Johnson were worth $13,959,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of JNJ. Lenox Wealth Advisors Inc. raised its position in shares of Johnson & Johnson by 0.7% in the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after buying an additional 6 shares during the period. Thomas J. Herzfeld Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $117,000. Empirical Finance LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $144,000. Foundation Resource Management Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $204,000. Finally, New Capital Management LP purchased a new position in shares of Johnson & Johnson during the fourth quarter valued at approximately $214,000. 66.02% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson (NYSE JNJ) traded down 0.38% during trading on Tuesday, reaching $131.65. 1,184,813 shares of the company’s stock were exchanged. The firm has a market capitalization of $354.64 billion, a price-to-earnings ratio of 22.13 and a beta of 0.78. The stock has a 50-day moving average price of $130.42 and a 200 day moving average price of $122.68. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.00.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.50% and a net margin of 22.87%. Johnson & Johnson’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.74 EPS. Equities research analysts forecast that Johnson & Johnson will post $7.10 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 56.47%.
COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (NYSE:JNJ) Shares Bought by Capital Investment Advisors LLC” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://sportsperspectives.com/2017/07/18/johnson-johnson-nysejnj-shares-bought-by-capital-investment-advisors-llc-updated.html.
A number of equities analysts recently issued reports on the stock. Jefferies Group LLC reissued a “hold” rating and issued a $145.00 price target (up from $140.00) on shares of Johnson & Johnson in a research note on Friday. Royal Bank Of Canada reaffirmed a “buy” rating and set a $138.00 target price on shares of Johnson & Johnson in a research note on Wednesday, July 12th. BidaskClub cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Wells Fargo & Company reiterated a “market perform” rating and set a $135.00 price target (up previously from $132.00) on shares of Johnson & Johnson in a report on Thursday, July 6th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 5th. Eleven investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $133.65.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.